A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Who May Qualify: - Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician. - Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study - UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies Who Should NOT Join This Trial: - Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug \[whichever is longer\] prior to baseline) - Prior treatment with Upadacitinib - Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study Always talk to your doctor about whether this trial is right for you.